The primitive face is composed of neural crest cell (NCC) derived prominences. The medial nasal processes (MNP) give rise to the upper lip and vomeronasal organ, and are essential for normal craniofacial development, but the mechanism of MNP development remains largely unknown. PDGFRa signaling is known to be critical for NCC development and craniofacial morphogenesis. In this study, we show that PDGFRa is required for MNP development by maintaining the migration of progenitor neural crest cells (NCCs) and the proliferation of MNP cells. Further investigations reveal that PI3K/Akt and Rac1 signaling mediate PDGFRa function during MNP development. We thus establish PDGFRa as a novel regulator of MNP development and elucidate the roles of its downstream signaling pathways at cellular and molecular levels.
Introduction
Neural crest cells (NCCs) are a transient and multipotent cell population unique to vertebrates. During development, NCCs give rise to a broad variety of cell types, which contribute to the formation of the peripheral nervous system, cardiac outflow tract, pigment cells, and the majority of craniofacial bones and cartilages [1] [2] [3] [4] . Alterations of cranial NCC (cNCC) development often lead to craniofacial malformations, one of the most prevalent birth defects [5] . These facts underscore the significance of understanding the mechanisms regulating NCCs during craniofacial morphogenesis.
At the onset of craniofacial development, the facial primordium is composed of five prominences surrounding the stomodeum: the frontonasal prominence (FNP) at the rostral region, two paired maxillary processes in the middle, and a pair of mandibular processes at the caudal end [6, 7] . These primordia are populated predominantly by NCC derived cells, surrounding a mesodermal core and covered by the overlying ectoderm. The ectoderm then thickens and invaginates to form two bilateral nasal placodes, dividing the FNP into the medial nasal process (MNP) and a pair of lateral nasal processes (LNP). The MNP and bilateral maxillary processes contribute together to form the upper lip [8] . In mammals, the MNP further develops into the philtrum and the nasal septum, which later forms the nasal cartilage and bone [9] . Disruption of the MNP usually causes a variety of craniofacial defects, ranging from mild hypoplasia of the nasal bones to complete midfacial clefting. A number of genes regulate maxilla and mandible development, but it remains largely unknown how MNP development is controlled at the molecular and cellular level. Vital dye labeling studies reveal that the NCCs giving rise to different facial prominences share distinct origins along the rostralcaudal axis: NCCs from the diencephalon and anterior mesencephalon give rise to the MNP and LNP, while those originating from the posterior mesencephalon and hindbrain give rise to the maxilla and mandible [10, 11] . These results suggest that the MNP and other prominences may be regulated through different mechanisms.
Multiple genetic factors have been implicated in cranial NCC (cNCC) development. Among these, growth factor signaling pathways are essential for induction, proliferation, survival and migration [12] [13] [14] . BMP, FGF and Wnt signaling together mediate induction of cNCCs from neural ectoderm [13, 15] . cNCC proliferation and survival are under the control of BMP, FGF and TGFb signaling, and migration of the cNCCs at the caudal level is regulated by BMP, Wnt, Semaphorin and Ephrin signaling [13] . Growth factors act via binding and activation of their cell surface receptors, which in turn engage multiple intracellular signaling pathways. It remains to be elucidated how these intracellular signaling pathways mediate the receptors' function, especially in developmental contexts.
Platelet Derived Growth Factor (PDGF) signaling plays essential roles in development and disease [16] [17] [18] [19] . In mammals, PDGF signaling can be activated by four PDGF ligands (A, B, C and D) operating through two receptor tyrosine kinases, PDGFRa and b [17, 20] . Activation of PDGFRs leads to phosphorylation of intracellular tyrosines and docking of intracellular effectors, which in turn engage downstream signaling cascades including the MAPK, PI3K, PLCc, STAT and Src pathways. Previous studies from our laboratory and others have shown that PDGFRa and its downstream signaling pathways are crucial for cardiac and cranial NCCs [21] [22] [23] [24] . PDGFA/PDGFRa signaling has also been implicated in cell migration in zebrafish palatogenesis [25] . However, the precise mechanisms by which PDGFRa regulates cNCCs and MNP development still remain to be elucidated. To this end, we have carried out a detailed study of PDGFRa NCC conditional knockout embryos. Our work reveals novel roles of PDGFRa in regulating NCC migration, and for PDGFRa engaged PI3K signaling in MNP neural crest cell proliferation. Moreover, we show that Rac1 and PI3K signaling mediate these processes under the control of PDGFRa.
Results

Loss of PDGFRa leads to facial clefting due to loss of MNP derived structures
To understand how PDGFRa and its downstream signaling pathways regulate NCC development and craniofacial morphogenesis, we generated NCC-specific PDGFRa conditional knockout (cKO) embryos by intercrossing PDGFRa fl/fl and Wnt1Cre transgenic mice [21, 26] . Morphological differences first became visible at E11.5, as the medial nasal processes (MNP) of cKO littermates remained separated by an obvious gap relative to the control embryos (Fig. 1A, B) . By E13.5, cKO embryos lacked the philtrum and the primary palate (Fig. 1C, D) , both of which are derived from the MNP. This observation was confirmed by histological analysis that showed the absence of the primary palate and philtrum in the cKO embryos (Fig. 1E, F) . At E18.5, skeletal preparations showed that PDGFRa fl/fl ; Wnt1 Cre embryos exhibited a significant cleft (6 out of 6) and shortening of nasal cartilage (8864.8% relative to control) and premaxilla (81.262.0% relative to control) (Fig. 1G, H) . Skeletal analysis of cKO mutants also revealed malformation of the neural crest derived basisphenoid, alisphenoid and pterygoid bones (Fig. 1G,  H) [1, 27, 28] . Other cNCC derived structures, such as the mandible, developed normally in the cKO mutants. No cKO embryos survived past birth.
To further understand how PDGFRa signals during MNP development, we analyzed the expression of PDGFRa and its ligands. Using PDGFRa GFP/+ knockin reporter mice [29] , we observed broad GFP expression in the facial structures at E10.5 ( Fig. 2A) . Coronal sections of PDGFRa GFP/+ embryos at different stages revealed that PDGFRa is exclusively expressed in mesenchymal cells of the future facial structures, which are derived predominantly from cNCCs [1] . At E10.5, PDGFRa appears to be expressed equally in both the MNP and the LNP (Fig. 2B) ; however by E11.5, PDGFRa expression is reduced in the LNP relative to the MNP mesenchyme (Fig. 2C) . PDGFA and PDGFC 
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encode two endogenous ligands that bind specifically to PDGFRa, and inactivation of the two genes together recapitulates the PDGFRa null mutant phenotype [30] . In situ hybridization showed that these genes exhibit overlapping expression in the MNP: PDGFA is expressed in the MNP and LNP epithelium and PDGFC is expressed in both the epithelium and mesenchyme (Fig. 2D-G) . The expression patterns of PDGFRa and its ligands indicate paracrine and possibly autocrine PDGFRa signaling during MNP development.
PDGFRa regulates cell proliferation in the FNP and MNP through PI3K signaling
To examine the role of PDGFRa in the MNP, we first analyzed cell proliferation and apoptosis in developing embryos. BrdU labeling revealed that in control embryos (n = 9), 4063% of MNP mesenchymal cells and 3562% of LNP mesenchymal cells were proliferating at E11.5. In cKO embryos, MNP mesenchymal cell proliferation was decreased by 30% relative to littermate controls, while LNP mesenchymal cell division was maintained a comparable level (Fig. 3A, B and E). No ectopic apoptosis was identified in cKO MNP cells (data not shown). Since the MNP and LNP are derived from the FNP during embryogenesis, we further traced these defects to the FNP. We found that at E9.5, cKO FNP mesenchymal cell proliferation was significantly downregulated by 19% ( Fig. 3C-E) , and no ectopic cell apoptosis was identified (data not shown). We also assayed expression of genes critical for MNP development in E10.5 embryos. Among them, Six1 and Alx4 expression remained unaltered in cKO and control embryos (Fig.   S1 ), while Alx3 expression was downregulated in the cKO MNP mesenchyme, but not in the mandible (Fig. 3F, G) . Because Alx3 is essential for MNP cell survival and no ectopic apoptosis was found in the cKO MNP (data not shown) [31] , the reduction of Alx3 mRNA might be caused by a decrease in cell number in the cKO MNP. A similar change in gene expression has been observed in Pax6 mutant embryos, which showed a migration defect of MNP progenitor cells [32] . Together, these data suggest that PDGFRa regulates cell proliferation in the FNP and specifically in the MNP.
PDGFRa regulates cell fates and behaviors through a number of downstream signaling pathways. Previous studies in our laboratory showed that PI3K signaling is the major effector of PDGFRa in craniofacial development. Loss of PDGFRa-mediated PI3K signaling alone caused cleft palate with incomplete penetrance, but inactivation of PDGFRa together with PDGFRbmediated PI3K signaling caused facial clefting similar to PDGFRa null mutant embryos [24] . To examine the role of PI3K signaling in MNP development, we first analyzed the phenotype of PDGFRa PI3K/PI3K mice. PDGFRa PI3K/PI3K embryos exhibited a shortened nasal septum at E13.5 ( Fig. 4A , B) and shortened nasal bones at E18.5 ( Fig. 4C, D) . The mutant nasal cartilage was 10% shorter than the heterozygous control and the premaxilla was 14% shorter than the control (n = 5, p,0.05). As with the cKO MNP, BrdU labeling results revealed that a decrease in cell proliferation in the MNP of PDGFRa PI3K/PI3K embryos at E11. decrease in cell proliferation (data not shown). Together these results indicate that PI3K signaling is essential for PDGFRaregulated neural crest derived cell proliferation.
Neural crest cells fail to populate the frontonasal area efficiently
Lineage studies have revealed that MNP cells are predominantly derived from NCCs [1, 2] . To be able to trace NCCs in the conditional mutants, we introduced the R26R Cre reporter allele [33] into the PDGFRa fl/fl ; Wnt1Cre background. CKO and control embryos were age matched by counting the number of somites. Lineage tracing showed that at E8.5 LacZ reporter expression was comparable in cKO and control embryos (Fig. 5A-D , cKO n = 7, ctrl n = 11), indicating that PDGFRa is not critical for neural crest specification. This observation was confirmed by quantifying the expression of neural crest marker genes Sox10 and Ap2a in E8.5 embryos using RT q-PCR (Fig. 5E, n = 3) . By E9.5 however, R26R expression was attenuated in the cKO FNP as compared to the control ( Fig. 5F -I, cKO n = 4, ctrl n = 15). Consistent with the above observations, Sox10 expression was also disrupted in E9.5 cKO embryos (Fig. 5J, K) . At E10.5, cKO embryos showed fewer NCCs in pharyngeal arches III to VI (Fig. 5L , M, cKO n = 5, ctrl n = 7) and abnormal bifurcation of the NCCs streams migrating to these pharyngeal arches was observed in some embryos (Fig. S4A, B) . Skeletal elements derived from these structures including the hyoid bone, the stapes, and the styloid process were severely deformed or missing in cKO embryos at E18.5 ( Fig. S4C-H, n = 6 ). The cell lineage tracing results, along with the altered gene expression signature and defects in skeletal development indicate that PDGFRa is essential for NCCs to migrate in normal numbers and populate craniofacial regions.
Defective migration and morphology of cKO NCCs
To analyze the function of PDGFRa in NCC migration, explant cultures were established from the cranial neural tube (anterior to the first pharyngeal arch) of cKO and control embryos. To uncouple potential cell migration defects from alterations in cell proliferation, explants were plated on fibronectin in the presence of mitomycin C. The explant cultures exhibited a significant decrease in emigration of cKO NCC cells (Fig. 6A-D, n = 3 ). Moreover morphometric analysis indicated that primary cKO NCC cells were significantly smaller (33.1%) than control cells (n = 50), and exhibited fewer lamellipodia (Fig. 6E, F) , which are required for cell migration. The cKO NCCs also exhibited an increased nuclear-cytoplasmic ratio (12.7% in cKO cells and 4.3% in wild type cells), as well as fewer focal adhesions (34.5 per cKO cell and 89.1 per wild type cell, n = 50; Fig. 6 G) .
These results suggest that PDGFRa is essential for neural crest cell motility, possibly by regulating cytoskeletal architecture. Alternatively, PDGFA/PDGFRa might also regulate NCC migration by regulating cell guidance [25, 34] . To distinguish between these possibilities, we carried out further experiments in primary MEPMs at passage 1. PDGFA acted as a chemoattractant of primary MEPMs in transwell assays (Fig. 7A ). In addition, PDGFA treatment sped up the wound healing rate of MEPMs (Fig. 7B) . These data indicate that activation of PDGFRa plays dual roles in neural crest derived cell migration, by stimulating chemotaxis and by regulating cell motility. To investigate if PI3K signaling plays a role in NCC migration, we generated PDGFR PI3K/PI3K ; Wnt1Cre; R26R +/2 embryos. Lineage tracing showed no obvious cNCC migration defects in PDGFRa PI3K/PI3K ; Wnt1Cre; R26R +/2 embryos (Fig. S5 , n = 6). Transwell assays revealed that PDGFRa PI3K/PI3K MEPMs respond and migrate towards a source of PDGFA at a level comparable to wild type cells (Fig. 7C) . In addition, the wound healing speed of PDGFRa PI3K/PI3K MEPMs remains comparable to that of heterozygous cells in a scratch assay (Fig. 7D) . In summary, these results indicate that PI3K signaling engaged by PDGFRa is not essential for cell migration, in contrast to its role in regulating proliferation of neural crest derived cells during development.
Rac1 signaling mediates PDGFRa regulation of proliferation and migration of MEPMs
The abnormal morphology of cKO NCCs indicates other signaling might be essential to regulate the cytoskeleton downstream of PDGFRa. Rho GTPases constitute a group of major regulators of cell migration that mediate actin reorganization, and lamellipodia and filopodia formation [35, 36] . PDGF and PI3K/ Akt signaling have been shown to phosphorylate guanine nucleotide-exchange factors (GEFs), which in turn prompt the formation of GTP-bound, active small GTPases such as RhoA, Cdc42 and Rac1 [37] [38] [39] [40] . Inactivation of Rac1 in NCCs caused facial clefting, strikingly resembling the PDGFRa cKO phenotype [41, 42] , suggesting Rac1 to be a potential mediator of PDGFRa in NCC development. Rac1 activity was attenuated in lysates of E10.5 cKO MNP cells (Fig. 8A) , and we observed a reduction in the expression of phosphorylated cofilin 1, an actin depolymerization enzyme required for cNCC development (Fig. 8 B) [43] . PDGFA stimulation facilitates phosphorylation of cofilin in MEPMs (Fig. 8C) , indicating that PDGFRa can regulate Rac1 activity in neural crest derived cells. Consistent with an important role for Rac1 in mediating PDGF driven functions, treatment of MEPMs with the Rac1 specific inhibitor NSC 23766 blocked PDGFA stimulated proliferation and wound healing (Fig. 8D, E) . Further examination revealed that inactivation of Rac1 affected lamellipodia formation at the leading edge of migrating MEPMs, reminiscent of the phenotype of PDGFRa deficient MEPMs (Fig. 8F-K) . Inhibition of Rac1 activity in MEPMs also led to smaller size (31% of untreated cells, n = 50), fewer focal adhesion complexes (22.1 per treated cell vs. 83.2 per untreated cell, n = 50), and increased nuclear-cytoplasmic ratio (9% in treated cells vs. 5% in untreated MEPMs, n = 50) (Fig. 8L) . Taken together, these results indicate a prominent role for Rac1 in the regulation of PDGF-induced cell migration and proliferation.
Discussion
Facial clefting is a rare birth defect and its etiology remains poorly understood. In this work, we show that the facial clefting phenotype of PDGFRa mutants is not associated with a defect in NCC specification but rather a subsequent defect in the medial nasal process (MNP), a facial primordium derived from the frontonasal prominence (FNP). We further show that this defect is associated with alterations in both cell proliferation and cell migration, and that PI3K and Rac1 signaling are essential to maintain a normal level of cell proliferation. Last, we provide evidence that Rac1 regulates cell migration at the level of cell motility as well as chemotaxis under the regulation of PDGFRa.
A previous study from our laboratory had shown that the facial clefting observed in PDGFRa mutants was of neural crest origin, using chimeric analysis and conditional mutagenesis with the E18.5 embryos develop hypoplastic nasal cartilages and shorter premaxilla bones than control (C Wnt1Cre driver [21] . Although global defects in cell proliferation and migration were not documented, chimeric analysis identified a role for PDGFRa in development of the pharyngeal arches, which we now show by lineage tracing are deficient in cNCCs by E10.5 in cKO embryos. In this work, we have considerably refined the analysis by examining specific rather than overall craniofacial subregions. We were thus able to document disruption of cell migration in the FNP by cell lineage analysis at E9.5, and of cell proliferation in the MNP of cKO embryos by E10.5. Therefore, both the previous study and the present work identify a crucial role for PDGFRa in NCC development.
We found that PDGFRa exhibits a strong expression pattern in the MNP mesenchyme at different stages. PDGFA is expressed in the MNP epithelium, and PDGFC is expressed in both the MNP epithelium and the mesenchyme, consistent with paracrine or autocrine PDGFRa signaling during craniofacial development. Prior genetic evidence from our lab, using point mutations in the PI3K binding sites in the PDGFRs, has implicated PI3K as the key signaling pathway regulating craniofacial development [24] . We also found that that PI3K signaling regulates p44/42 MAPK (data not shown). Strikingly, mice carrying a neural crest-specific deletion of Erk1/Erk2 display facial clefting [23] . p44/42 MAPK can also be engaged by other pathways than PI3K, and by other RTKs that are critical for craniofacial development including Fgfrs, Eph receptors, EGFR, Ror or Ryk. Although these RTKs share some similar intracellular domains and engage overlapping signaling pathways, their impact on craniofacial development might reflect tissue-restricted expression patterns of receptors and ligands, as well as engagement of unique combinations of downstream signaling cascades. It will be important to understand if the phenotypic differences associated with different RTKs are due to dosage variation of PI3K signaling, involvement of other unique signaling pathways, or a combination of both.
Neural crest cells form through delamination of cells at the lateral plate border of the neural tube that undergo an epithelial to mesenchymal transition. There is extensive evidence that cell-cell contacts through intricate lamellipodial and filipodial extensions play critical roles in regulating how cells exit the neural tube and migrate to their proper destination (for a review, see [13] ). Small GTPases, including Rho, Rac and Cdc42 are well known to regulate such cell behaviors, but also cell proliferation and gene transcription under the regulation of multiple RTKs [44] . Recent gene targeting studies showed that inactivation of Rac1 or Cdc42, or overexpression of a dominant negative Rho kinase in mouse NCCs causes a severe facial clefting phenotype, which strikingly resembles PDGFRa homozygous mutant embryos [21, 22, 41, 42, 45] . In particular, Rac1 deficient NCCs exhibit decreased proliferation, abnormal cell morphology, as well as disrupted lamellipodia formation [42] , very similar to the defects we have observed in PDGFRa deficient NCCs and MEPMs. The notion that PDGFRa might be a major regulator of Rac1 activity is further supported by our present work and other studies that show that PDGFA stimulates Rac1-GTP levels in a variety of biological settings [46] [47] [48] . It has been suggested that EGFR could be the major effector of the Rac1 mutant phenotype [41] , as EGF has been used as an agonist of Rac1 activity in a variety of in vitro studies. However EGFR null mutant mice exhibit a much milder craniofacial phenotype with only a cleft palate. In addition, gene expression data showed that EGFR and Rac1 only partially overlap in ectodermal cells during early stages of craniofacial morphogenesis (Emage, www.emouseatlas.org), whereas PDGFRa shows a broad expression pattern similar to Rac1 in cNCCs at E10.5. Functionally, PDGFRa deficient NCCs exhibit abnormal morphology and defective formation of lamellipodia and focal adhesions. These lines of evidence point to a major role for Rac1 in mediating PDGFRa functions in NCC development and craniofacial morphogenesis.
Materials and Methods
Ethics statement
The Mount Sinai School of Medicine Institutional Animal Care and Use Committee (IACUC) approved all animal work and procedures used in this study. The Mount Sinai animal facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). , PDGFRa PI3K/+ , Wnt1Cre and R26R mice have been described previously [21, 24, 26, 29, 33] . PDGFRa fl/fl , PDGFRa PI3K/+ and Wnt1Cre mice were maintained on a 129S4 co-isogenic genetic background, and PDGFRa GFP/+ and ROSA26R mice were kept on a C57BL/6J co-isogenic background. Mice and embryos used in lineage tracing studies were maintained on a mixed genetic background.
Mice and genotyping
Histology, skeletal analysis, immunostaining, in situ hybridization and X-gal staining For histology, staged embryos were dissected in ice-cold PBS, fixed in Bouin's fixative, dehydrated through a graded series of ethanol washes, and embedded in paraffin. Sections were cut at 10 mm for hematoxylin and eosin staining. Skeletal analysis was performed on E18.5 embryos as described [22] . Craniofacial morphometry was performed as described in Fig. S6 . For immunostaining, embryos were fixed in 4% PFA overnight at 4uC, dehydrated in 30% sucrose/PBS and embedded in OCT.
Cryosections were prepared at a thickness of 10 mm. Immunostaining was performed according to standard protocols using antibodies to PDGFRa (1:60; Santa Cruz), vinculin (1:200, Sigma), BrdU (1:500, DSHB), Cleaved-Caspase 3 (1:200, Cell Signaling Technology) and rhodamine phalloidin (0.2 mM, Biotium). For in situ hybridization, embryos were dissected in ice-cold PBS, fixed in 4% paraformaldehyde (PFA), dehydrated through graded ethanol washes, and embedded in paraffin. Coronal sections were cut at 10 mm and in situ hybridization was performed as described [49] . X-gal staining was performed as described [33] .
Cell proliferation analysis
To measure cell proliferation rates in vivo, BrdU was injected intraperitoneally into pregnant females at a dosage of 50 mg per gram of body weight. Embryos were dissected after 1 hour, fixed in 4% PFA and processed for cryosections and immunostaining using standard protocols. BrdU labeled cells were counted in a random area in the defined mesenchyme at comparable levels in mutant and control samples. Three continuous sections were counted from each of triplicate samples. The result of BrdU labeling was presented as percentage of BrdU-positive cells against total nuclei labeled by DAPI. Student's t-test was used to determine statistical significance.
Neural crest explant cultures
Neural tubes anterior to the first pharyngeal arch were dissected from E8.5 embryos. Following two brief washes in ice-cold PBS, heads were sagitally split into two equal halves. The tissue was incubated in 0.5% trypsin/2.5% pancreatin in PBS for 5 minutes on ice, and then in DMEM with 10% FBS for 10 minutes to stop the reaction. The head mesenchyme was carefully dissected and isolated with fine-tipped Dumont #5 tweezers, and the neural tube was transferred to fibronectin-coated cover slips in a 6 well plate. For NCC emigration assays, neural tubes were cultured in DMEM/F12 with 10% FBS for 6 hours. The explants were then treated with low serum media (DMEM/F12 containing 0.5% FBS) with 10 mg/ml mitomycin C for two hours. The culture medium was replaced with low serum media and maintained for 24 hours.
Results were recorded at 8 hours and 24 hours respectively. The explants were then removed and the emigrating cells were subjected to immunostaining.
Cell culture, scratch assay and transwell assay Primary Mouse Embryonic Palatal Mesenchymal cells (MEPMs) were isolated as described [50] . For scratch assays, MEPMs at passage 1 were seeded on fibronectin-coated cover slips in 6 well plates at a density of 100,000 cells per well. After reaching 70-80% confluency, cells were starved for 24 hours in DMEM containing 0.5% FBS. In some experiments, serum starved cells were pretreated with 30 mM Rac1 inhibitor NSC23766 (R&D Systems) for 3 hrs before stimulation with 30 ng/ml PDGFA. The scratch was mechanically created using a sterile P200 pipette tip and washed twice with starving medium to remove cell debris. The wound area was then photographed at marked positions (3 different fields per well). Cells were allowed to migrate for 12 hours at 37uC before the same fields were recorded. All experiments were performed in triplicate. Scratch results were measured with Image J software (NIH, Bethesda, USA) and analyzed using the extension package MiToBo [51] .
For transwell assays, cell culture inserts for a 24-well plate (Fisher) with a pore size of 8 mm were coated with fibronectin. P1 MEPMs were trypsinized, washed, and suspended in serum free medium at a concentration of 5610 6 cells/ml. 300 ml of cell suspension was added to the insert chambers immersed in 500 ml medium with 10% FBS, 0.5% FBS, or 0.5% FBS with PDGFAA. After incubation at 37uC and 5% CO2 for 3.5 hours, the inserts were fixed in 3.7% formaldehyde and stained in Mayer's hematoxylin solution. Filters of the inserts were then isolated with a scalpel and mounted. The numbers of cells on the bottom were counted. Data were recorded from 9 high power fields from three independent experiments.
Western blot and Rac1 activity analysis
Western blot analysis was carried out as described previously [24] , using primary antibodies from Abcam: anti-cofilin (phospho-S3) and from Cell Signaling Technology: anti-cofilin, anti-p44/42 MAPK, anti-phospho p44/42 MAPK, anti-Akt, anti-phospho-Akt (Ser473). Chemical inhibitors for MAPK (U0126, Promega), PI3K/Akt (LY294002, Stemgent) and Rac1 (NSC23766, R&D systems) were used in lysate generation for western blot analysis and the Rac1 activity assay, following the manufacturers' instruction. Rac1 activity analysis was performed using the colorimetric based G-LISA Rac1 Activation Assay Biochem Kit (Cytoskeleton Inc.). 
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